QuantHealth

About QuantHealth

QuantHealth provides an AI-powered platform that simulates clinical trials to de-risk and accelerate drug development for pharmaceutical and biotech companies. The company was founded in 2020 in Tel Aviv, Israel, by CEO Orr Inbar and CBO Arnon Horev. The founders identified that over 90% of drugs fail in clinical trials, costing the industry billions annually, and created QuantHealth to address this challenge. Inbar has a background in data science, AI, and biomedical research, with an MA in Information Technology from Harvard University and a B.Sc in Biochemistry from UMass-Amherst. He previously co-founded ConcertAI, a precision oncology company where he led data science and engineering. Horev has a business background in digital health and diagnostic companies, previously leading business operations at Nucleai and managing marketing at EarlySense. Their combined expertise in technology and life sciences underpins the company's mission. QuantHealth's core product is its Clinical-Simulator platform. This AI engine is trained on a massive dataset, including anonymized data from 350 million patients, biomedical knowledge graphs, and clinical trial data. The platform creates a "digital-drug and digital-twin in-one" environment, allowing clients to simulate thousands of trial variations by predicting how individual patients will respond to specific treatments. This enables the optimization of trial protocols, patient subgroup selection, and endpoint analysis before a trial begins, achieving a reported prediction accuracy of up to 90%. The technology supports various therapeutic areas, including oncology, immunology, and cardiovascular disease. The company operates on a B2B model, with a revenue structure that includes service fees and subscriptions. Engagements often start with a pilot phase to demonstrate proof of technology and value, which can then transition into longer-term partnerships. Its clients range from small biotechs to large pharmaceutical corporations, including 12 of the top 20 global pharma companies. The company has steadily grown its funding, securing a $15M Series A in 2023, and a $45M Series B in 2026 to fuel commercial expansion, R&D, and product portfolio growth. Keywords: clinical trial simulation, AI drug development, pharmaceutical AI, trial outcome prediction, in-silico trials, drug development optimization, patient response modeling, de-risking clinical trials, computational biology, synthetic trial data, pharmaco-clinical foundation model, trial protocol design, real-world data analytics, precision medicine, life sciences technology, clinical development, drug discovery AI, healthcare data analysis, virtual patient models, trial success probability